The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

Abdominal aortic aneurysm (AAA) is a common disease that develops from degeneration of the aortic wall. The natural history of AAA is gradual expansion and if left untreated may result in rupture and death. The mechanism of the development of this disease is unknown however it appears to be multifactorial and possibly related to degradation processes within the arterial wall. There is growing evidence that Angiotensin receptor blockers ( ARBS) may have an inhibitory effect on remodelling processes within the arterial wall, thus inhibiting degeneration of the vessel wall.

Study hypothesis: ARBS are associated with smaller diameters of aortas among hypertensive patients, and are associated with a lower rate of aortic expansion compared to other antihypertensive drugs.

Study Overview

• Status: Unknown
• Conditions: Hypertension; Aneurysm

• Study Type: Observational
• Enrollment (Anticipated): 150

Contacts and Locations

• Study Contact: Name: Daniel Silverberg, MD; Phone Number: 035302712; Email: Daniel.Silverberg@sheba.health.gov.il

Study Locations

• Israel
  • Tel Hashomer, Israel
    • Recruiting
    • Sheba Medical Center
    • Contact: Daniel Silverberg, MD; Email: Daniel.Silverberg@sheba.health.gov.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

medically treated hypertensive patients, ages 50-80

Description

Inclusion Criteria:

• medically treated hypertensive patients, ages 50-80

Exclusion Criteria:

• pregnant women
• patients previously treated for aortic disease
• unable to sign informed consent, minors

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
ARBs; Hypertensive patients treated with ARBs
ACE inhibitors; Hypertensive patients treated with ACE inhibitors
non ARB/ACE; Hypertensive patients treated with non ARBs or ACE inhibitors meds

Collaborators and Investigators

• Sponsor: Sheba Medical Center
• Investigators: Principal Investigator: Daniel Silverberg, MD, Sheba Medical Center

Study record dates

Study Major Dates

• Study Start: May 1, 2011

Study Registration Dates

• First Submitted: August 19, 2012
• First Submitted That Met QC Criteria: August 19, 2012
• First Posted (Estimate): August 22, 2012

Study Record Updates

• Last Update Posted (Estimate): August 22, 2012
• Last Update Submitted That Met QC Criteria: August 19, 2012
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Aneurysm
• Other Study ID Numbers: SHEBA-12-8336-DS-CTIL